Target Price | $3.78 |
Price | $1.12 |
Potential |
237.30%
register free of charge
|
Number of Estimates | 9 |
9 Analysts have issued a price target Editas Medicine, Inc. 2026 .
The average Editas Medicine, Inc. target price is $3.78.
This is
237.30%
register free of charge
$8.00
614.29%
register free of charge
$1.00
10.71%
register free of charge
|
|
A rating was issued by 15 analysts: 5 Analysts recommend Editas Medicine, Inc. to buy, 8 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Editas Medicine, Inc. stock has an average upside potential 2026 of
237.30%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 32.31 | 9.52 |
58.64% | 70.55% | |
EBITDA Margin | -721.48% | -1,259.13% |
245.52% | 74.52% | |
Net Margin | -737.43% | -1,233.88% |
244.72% | 67.32% |
12 Analysts have issued a sales forecast Editas Medicine, Inc. 2025 . The average Editas Medicine, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Editas Medicine, Inc. EBITDA forecast 2025. The average Editas Medicine, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Editas Medicine, Inc. Analysts have issued a net profit forecast 2025. The average Editas Medicine, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.88 | -1.42 |
42.57% | 50.69% | |
P/E | negative | |
EV/Sales | negative |
4 Analysts have issued a Editas Medicine, Inc. forecast for earnings per share. The average Editas Medicine, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Editas Medicine, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Evercore ISI Group |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
JP Morgan |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
RBC Capital |
Locked
➜
Locked
|
Locked | Dec 13 2024 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Dec 13 2024 |
Barclays |
Locked
➜
Locked
|
Locked | Dec 13 2024 |
Baird |
Locked
➜
Locked
|
Locked | Dec 13 2024 |
Stifel |
Locked
➜
Locked
|
Locked | Dec 13 2024 |
Analyst Rating | Date |
---|---|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Dec 16 2024 |
Locked
JP Morgan:
Locked
➜
Locked
|
Dec 16 2024 |
Locked
RBC Capital:
Locked
➜
Locked
|
Dec 13 2024 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Dec 13 2024 |
Locked
Barclays:
Locked
➜
Locked
|
Dec 13 2024 |
Locked
Baird:
Locked
➜
Locked
|
Dec 13 2024 |
Locked
Stifel:
Locked
➜
Locked
|
Dec 13 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.